- Home
- PHAT vs TRIN Comparison
PHAT vs TRIN Comparison
Compare PHAT & TRIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- TRIN
- Stock Information
- Founded
- PHAT 2018
- TRIN 2007
- Country
- PHAT United States
- TRIN United States
- Employees
- PHAT N/A
- TRIN N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- TRIN Finance/Investors Services
- Sector
- PHAT Health Care
- TRIN Finance
- Exchange
- PHAT Nasdaq
- TRIN Nasdaq
- Market Cap
- PHAT 942.6M
- TRIN 1.0B
- IPO Year
- PHAT 2019
- TRIN 2021
- Fundamental
- Price
- PHAT $14.85
- TRIN $14.42
- Analyst Decision
- PHAT Strong Buy
- TRIN Buy
- Analyst Count
- PHAT 5
- TRIN 4
- Target Price
- PHAT $17.60
- TRIN $15.63
- AVG Volume (30 Days)
- PHAT 983.2K
- TRIN 818.1K
- Earning Date
- PHAT 10-30-2025
- TRIN 11-05-2025
- Dividend Yield
- PHAT N/A
- TRIN 14.19%
- EPS Growth
- PHAT N/A
- TRIN 25.79
- EPS
- PHAT N/A
- TRIN 2.17
- Revenue
- PHAT $147,190,000.00
- TRIN $268,271,000.00
- Revenue This Year
- PHAT $218.38
- TRIN $27.19
- Revenue Next Year
- PHAT $87.14
- TRIN $8.97
- P/E Ratio
- PHAT N/A
- TRIN $6.64
- Revenue Growth
- PHAT 460.30
- TRIN 30.76
- 52 Week Low
- PHAT $2.21
- TRIN $12.50
- 52 Week High
- PHAT $16.08
- TRIN $16.82
- Technical
- Relative Strength Index (RSI)
- PHAT 64.62
- TRIN 38.49
- Support Level
- PHAT $14.12
- TRIN $14.33
- Resistance Level
- PHAT $15.28
- TRIN $15.05
- Average True Range (ATR)
- PHAT 0.93
- TRIN 0.27
- MACD
- PHAT 0.07
- TRIN -0.01
- Stochastic Oscillator
- PHAT 82.58
- TRIN 8.85
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About TRIN Trinity Capital Inc.
Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.